{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:02:59Z","timestamp":1776128579143,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,10]]},"DOI":"10.7759\/cureus.78810","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T12:21:36Z","timestamp":1739190096000},"source":"Crossref","is-referenced-by-count":1,"title":["Clarity Amidst the Smoke: Moyamoya Disease, a Diagnosis Not to Be Missed"],"prefix":"10.7759","author":[{"given":"Sharifa","family":"Alnaqeeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Kheder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor A","family":"Abotaiban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10141","article-title":"Moyamoya disease: a review of current literature","volume":"12","author":"Gupta A","year":"2020","unstructured":"Gupta A, Tyagi A, Romo M, Amoroso KC, Sonia F. Moyamoya disease: a review of current literature. Cureus. 2020, 12:e10141. 10.7759\/cureus.10141","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.7198","article-title":"Epidemiology, diagnosis and treatment of Moyamoya disease","volume":"17","author":"Zhang H","year":"2019","unstructured":"Zhang H, Zheng L, Feng L. Epidemiology, diagnosis and treatment of Moyamoya disease. Exp Ther Med. 2019, 17:1977-84. 10.3892\/etm.2019.7198","journal-title":"Exp Ther Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000443","article-title":"Adult Moyamoya disease and syndrome: current perspectives and future directions: a scientific statement from the American heart association\/American stroke association","volume":"54","author":"Gonzalez NR","year":"2023","unstructured":"Gonzalez NR, Amin-Hanjani S, Bang OY, et al.. Adult Moyamoya disease and syndrome: current perspectives and future directions: a scientific statement from the American heart association\/American stroke association. Stroke. 2023, 54:e465-79. 10.1161\/STR.0000000000000443","journal-title":"Stroke"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00165-X","article-title":"Moyamoya disease: diagnosis and interventions","volume":"21","author":"Ihara M","year":"2022","unstructured":"Ihara M, Yamamoto Y, Hattori Y, et al.. Moyamoya disease: diagnosis and interventions. Lancet Neurol. 2022, 21:747-58. 10.1016\/S1474-4422(22)00165-X","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1969.00480090076012","article-title":"Cerebrovascular \"Moyamoya\" disease. Disease showing abnormal net-like vessels in base of brain","volume":"20","author":"Suzuki J","year":"1969","unstructured":"Suzuki J, Takaku A. Cerebrovascular \"Moyamoya\" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969, 20:288-99. 10.1001\/archneur.1969.00480090076012","journal-title":"Arch Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.130666","article-title":"Novel epidemiological features of Moyamoya disease","volume":"79","author":"Baba T","year":"2008","unstructured":"Baba T, Houkin K, Kuroda S. Novel epidemiological features of Moyamoya disease. J Neurol Neurosurg Psychiatry. 2008, 79:900-4. 10.1136\/jnnp.2007.130666","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.107.490714","article-title":"Prevalence and clinicoepidemiological features of Moyamoya disease in Japan: findings from a nationwide epidemiological survey","volume":"39","author":"Kuriyama S","year":"2008","unstructured":"Kuriyama S, Kusaka Y, Fujimura M, et al.. Prevalence and clinicoepidemiological features of Moyamoya disease in Japan: findings from a nationwide epidemiological survey. Stroke. 2008, 39:42-7. 10.1161\/STROKEAHA.107.490714","journal-title":"Stroke"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2010.132","article-title":"A genome-wide association study identifies RNF213 as the first Moyamoya disease gene","volume":"56","author":"Kamada F","year":"2011","unstructured":"Kamada F, Aoki Y, Narisawa A, et al.. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2011, 56:34-40. 10.1038\/jhg.2010.132","journal-title":"J Hum Genet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2176\/nmc.ra.2019-0059","article-title":"Influence of inflammatory disease on the pathophysiology of Moyamoya disease and quasi-Moyamoya disease","volume":"59","author":"Mikami T","year":"2019","unstructured":"Mikami T, Suzuki H, Komatsu K, Mikuni N. Influence of inflammatory disease on the pathophysiology of Moyamoya disease and quasi-Moyamoya disease. Neurol Med Chir (Tokyo). 2019, 59:361-70. 10.2176\/nmc.ra.2019-0059","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2176\/jns-nmc.2022-0072","article-title":"Diagnostic criteria for Moyamoya disease - 2021 revised version","volume":"62","author":"Kuroda S","year":"2022","unstructured":"Kuroda S, Fujimura M, Takahashi J, et al.. Diagnostic criteria for Moyamoya disease - 2021 revised version. Neurol Med Chir (Tokyo). 2022, 62:307-12. 10.2176\/jns-nmc.2022-0072","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70240-0","article-title":"Moyamoya disease: current concepts and future perspectives","volume":"7","author":"Kuroda S","year":"2008","unstructured":"Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol. 2008, 7:1056-66. 10.1016\/S1474-4422(08)70240-0","journal-title":"Lancet Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2176\/nmc.52.327","article-title":"Lessons learned from Moyamoya disease: outcome of direct\/indirect revascularization surgery for 150 affected hemispheres","volume":"52","author":"Fujimura M","year":"2012","unstructured":"Fujimura M, Tominaga T. Lessons learned from Moyamoya disease: outcome of direct\/indirect revascularization surgery for 150 affected hemispheres. Neurol Med Chir (Tokyo). 2012, 52:327-32. 10.2176\/nmc.52.327","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3171\/2009.4.JNS081649","article-title":"Clinical outcome after 450 revascularization procedures for Moyamoya disease. Clinical article","volume":"111","author":"Guzman R","year":"2009","unstructured":"Guzman R, Lee M, Achrol A, et al.. Clinical outcome after 450 revascularization procedures for Moyamoya disease. Clinical article. J Neurosurg. 2009, 111:927-35. 10.3171\/2009.4.JNS081649","journal-title":"J Neurosurg"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-004-1118-9","article-title":"Revascularisation surgery for paediatric Moyamoya: a review of the literature","volume":"21","author":"Fung LW","year":"2005","unstructured":"Fung LW, Thompson D, Ganesan V. Revascularisation surgery for paediatric Moyamoya: a review of the literature. Childs Nerv Syst. 2005, 21:358-64. 10.1007\/s00381-004-1118-9","journal-title":"Childs Nerv Syst"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.608000","article-title":"Efficacy and safety of antiplatelet agents for adult patients with ischemic Moyamoya disease","volume":"11","author":"Ye F","year":"2020","unstructured":"Ye F, Li J, Wang T, et al.. Efficacy and safety of antiplatelet agents for adult patients with ischemic Moyamoya disease. Front Neurol. 2020, 11:608000. 10.3389\/fneur.2020.608000","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99009-1","article-title":"Benefits and risks of antiplatelet medication in hemodynamically stable adult Moyamoya disease","volume":"11","author":"Pang CH","year":"2021","unstructured":"Pang CH, Cho WS, Kang HS, Kim JE. Benefits and risks of antiplatelet medication in hemodynamically stable adult Moyamoya disease. Sci Rep. 2021, 11:19367. 10.1038\/s41598-021-99009-1","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.10.003","article-title":"Effects of surgery and antiplatelet therapy in ten-year follow-up from the registry study of research committee on Moyamoya disease in Japan","volume":"25","author":"Yamada S","year":"2016","unstructured":"Yamada S, Oki K, Itoh Y, et al.. Effects of surgery and antiplatelet therapy in ten-year follow-up from the registry study of research committee on Moyamoya disease in Japan. J Stroke Cerebrovasc Dis. 2016, 25:340-49. 10.1016\/j.jstrokecerebrovasdis.2015.10.003","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017701","article-title":"Association of antiplatelet therapy, including cilostazol, with improved survival in patients with Moyamoya disease in a nationwide study","volume":"10","author":"Seo WK","year":"2021","unstructured":"Seo WK, Kim JY, Choi EH, et al.. Association of antiplatelet therapy, including cilostazol, with improved survival in patients with Moyamoya disease in a nationwide study. J Am Heart Assoc. 2021, 10:e017701. 10.1161\/JAHA.120.017701","journal-title":"J Am Heart Assoc"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2020-000770","article-title":"Effects and safety of aspirin use in patients after cerebrovascular bypass procedures","volume":"6","author":"Lu J","year":"2021","unstructured":"Lu J, Shi G, Zhao Y, et al.. Effects and safety of aspirin use in patients after cerebrovascular bypass procedures. Stroke Vasc Neurol. 2021, 6:624-30. 10.1136\/svn-2020-000770","journal-title":"Stroke Vasc Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.841174","article-title":"Effects of aspirin therapy on bypass efficacy and survival of patients receiving direct cerebral revascularization","volume":"13","author":"Xiang Y","year":"2022","unstructured":"Xiang Y, Zhang P, Zhao P, et al.. Effects of aspirin therapy on bypass efficacy and survival of patients receiving direct cerebral revascularization. Front Pharmacol. 2022, 13:841174. 10.3389\/fphar.2022.841174","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2017.06.057","article-title":"Effect of aspirin in postoperative management of adult ischemic Moyamoya disease","volume":"105","author":"Zhao Y","year":"2017","unstructured":"Zhao Y, Zhang Q, Zhang D, Zhao Y. Effect of aspirin in postoperative management of adult ischemic Moyamoya disease. World Neurosurg. 2017, 105:728-31. 10.1016\/j.wneu.2017.06.057","journal-title":"World Neurosurg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009942","article-title":"Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic Moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study)","volume":"6","author":"Onozuka D","year":"2016","unstructured":"Onozuka D, Hagihara A, Nishimura K, et al.. Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic Moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study). BMJ Open. 2016, 6:e009942. 10.1136\/bmjopen-2015-009942","journal-title":"BMJ Open"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107389","article-title":"Long-term prognosis of 452 Moyamoya disease patients with and without revascularization under perfusion-based indications","volume":"32","author":"Hayashi T","year":"2023","unstructured":"Hayashi T, Hara S, Inaji M, et al.. Long-term prognosis of 452 Moyamoya disease patients with and without revascularization under perfusion-based indications. J Stroke Cerebrovasc Dis. 2023, 32:107389. 10.1016\/j.jstrokecerebrovasdis.2023.107389","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-021-04959-0","article-title":"Long-term mortality in patients with Moyamoya angiopathy according to stroke presentation type in South Korea","volume":"163","author":"Im SH","year":"2021","unstructured":"Im SH, Jang DK, Kim H, Park SK, Han KD. Long-term mortality in patients with Moyamoya angiopathy according to stroke presentation type in South Korea. Acta Neurochir (Wien). 2021, 163:3473-81. 10.1007\/s00701-021-04959-0","journal-title":"Acta Neurochir (Wien)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/283823-clarity-amidst-the-smoke-moyamoya-disease-a-diagnosis-not-to-be-missed","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T12:21:39Z","timestamp":1739190099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/283823-clarity-amidst-the-smoke-moyamoya-disease-a-diagnosis-not-to-be-missed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.78810","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,10]]}}}